Table 4

Patients with adverse events in the trials on rivastigmine and galantamine (actual data because testing for significance is not appropriate for rare effects because of insufficient power)

	No of patients			% of patients with adverse events on cholinesterase inhibitor (placebo) colsep=“0”
Study	Dose	Cholinesterase-inhibitor	Placebo	Diarrhoea	Nausea	Vomiting	Weight loss or anorexia	Dizziness	Other adverse events colsep=“0”
Rivastigmine colsep=“0”
Agid 199817	4 mg	136	133	7 (2)^*	17 (6)^*	10 (3)^*	—	6 (7)	— colsep=“0”
	6 mg	133		12 (2)^*	31 (6)^*	18 (3)^*	—	20 (7)^*	— colsep=“0”
Corey-Bloom 199818^†	1-4 mg	233	235	—	8 (3)^*	5 (2)^*	—	8 (4)	Dyspepsia: 6 (1)^* Sinusitis: 1 (1) colsep=“0”
	6-12 mg	231		—	20 (3)^*	16 (2)^*	—	14 (4)^*	Dyspepsia: 5 (1)^* Sinusitis: 4 (1)^* colsep=“0”
Forette 199919	6-12 mg twice daily	45	24	—	58 (8)^*	38 (4)^*	18 (0)^*	27 (0)^*	Headache: 16 (4) colsep=“0”
	6-12 mg thrice daily	45		—	58 (8)^*	31 (4)^*	16 (0)^*	9 (0)	Headache: 20 (4)^* colsep=“0”
Rösler 199920	1-4 mg	243	239	10 (9)	17 (10)^*	8 (6)	3 (2)	10 (7)	Headache: 7 (8) colsep=“0”
	6-12 mg	243		17 (9)^*	50 (10)^*	34 (6)^*	14 (2)^*	20 (7)^*	Headache: 19 (8)^* colsep=“0”
Potkin 200121	3-9 mg	20	7	—	—	—	—	—	— colsep=“0”
Galantamine colsep=“0”
Raskind 200022	24 mg	212	213	12 (10)	37 (13)^*	21 (8)^*	12 (5)^*	14 (11)	— colsep=“0”
	32 mg	211		19 (10)^*	44 (13)^*	26 (8)^*	11 (5)^*	19 (11)^*	— colsep=“0”
Rockwood 200123	24-32 mg	261	125	—	32 (11)^*	15 (4)^*	12 (2)^*	15 (4)^*	Agitation: 6 (1)^* Somnolence: 8 (1)^* colsep=“0”
Tariot 200024	8 mg	140	286	5 (6)	6 (5)	4 (1)	6 (3)	—	— colsep=“0”
	16 mg	279		12 (6)^*	13 (5)^*	6 (1)^*	7 (3)	—	— colsep=“0”
	24 mg	273		6 (6)	17 (5)^*	10 (1)^*	9 (3)^*	—	— colsep=“0”
Wilcock 200025	24 mg	220	215	7 (7)	37 (12)^*	20 (4)^*	8 (1)^*	11 (5)^*	Anorexia: 10 (0)^* colsep=“0”
	32 mg	218		13.(7)^*	40 (12)^*	17 (4)^*	5 (1)^*	12 (5)^*	Anorexia: 11 (0)^* colsep=“0”
Wilkinson 200126	18 mg	88	87	2 (2)	17 (3)^*	17 (5)^*	—	5 (3)	Headache: 6 (5) colsep=“0”
	24 mg	56		5 (2)	18 (3)^*	7 (5)	—	4 (3)	Headache: 11 (5)
	36 mg	54		4 (2)	37 (3)^*	17 (5)^*	—	7 (3)	Headache: 15 (5)^*

—=Not reported.
↵*Differences reach significance (P<0.05).
↵† Data shown represent the maintenance phase of the trial (week 8-26).